Influence of 3D-CRT and conformal IMRT on thyroid function of patients with cervical and upper thoracic esophageal cancer and comparison of clinical efficacy

Chen,Fei; Li,Jun; Ai,Nian; Zhang,Huaping; Li,Jun; Zhu,Yingying

doi:10.3892/ol.2019.9989

Influence of 3D-CRT and conformal IMRT on thyroid function of patients with cervical and upper thoracic esophageal cancer and comparison of clinical efficacy

Authors:
- Fei Chen
- Jun Li
- Nian Ai
- Huaping Zhang
- Yingying Zhu
View Affiliations

Affiliations: Department of Oncology, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei 432000, P.R. China, Department of Oncology, The Central Hospital of Xiaogan, Xiaogan, Hubei 432000, P.R. China, Cancer Center, Huazhong University of Science Technology Tongji Hospital, Sino-French New City Branch, Wuhan, Hubei 430100, P.R. China
Published online on: January 29, 2019 https://doi.org/10.3892/ol.2019.9989
Pages: 3432-3438
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical efficacy in patients with cervical and upper thoracic esophageal cancer was compared between three-dimensional conformal radiotherapy (3D-CRT) and conformal intensity-modulated radiotherapy (IMRT). Medical data of 120 esophageal cancer patients undergoing RT in the Radiology Department in Xiaogan Hospital Affiliated to Wuhan University of Science and Technology (Xiaogan, China) from March 2015 to March 2018 were retrospectively analyzed. Patients were divided into 3D-CRT group (treated with 3D-CRT, n=60) and IMRT group (treated with IMRT, n=60). The target conformal index (CI), PTV maximum dose (Dmax), PTV Dmin and PTV Dmean in both groups were observed. Changes in double-lung V5, double-lung V20, double-lung V30 and spinal cord Dmax in both groups were also observed. The serum free triiodothyronine (FT3), free tetraiodothyronine (FT4) and thyroid-stimulating hormone (TSH) concentrations were detected via chemiluminescence assay. Moreover, the short-term efficacy and radiation injury were observed. CI in IMRT group was significantly higher than that in 3D-CRT group (P<0.001). The organ-at-risk dose parameter V20 in IMRT group was obviously lower than that in 3D-CRT group (P<0.001). Serum FT3 and FT4 concentrations in both groups before RT were significantly higher than those after RT (P<0.05), but the TSH concentration was significantly lower than that after RT (P<0.05). Serum FT3 and FT4 concentrations in IMRT group after RT were obviously higher than those in 3D-CRT group (P<0.05). The incidence rates of radiation esophagitis and radiation pneumonitis in IMRT group were remarkably lower than those in 3D-CRT group (P<0.05). IMRT can reduce the double-lung V20 in patients, improve the target conformal degree, better protect the normal tissues, cause less damage to thyroid function, and reduce radiation injury during and after RT of esophageal cancer.

View Figures

View References

1	Caudell JJ, Carroll WR, Spencer SA and Bonner JA: Examination of laryngoesophageal dysfunction-free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynx. Cancer. 117:4447–4451. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P, Geh JI and Griffiths EA: Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: A network meta-analysis. Ann Surg. 265:481–491. 2017. View Article : Google Scholar : PubMed/NCBI
3	Chen J, Su T, Lin Y, Wang B, Li J, Pan J and Chen C: Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma. Clin Transl Oncol. 20:411–419. 2018. View Article : Google Scholar : PubMed/NCBI
4	Wong AT, Shao M, Rineer J, Lee A, Schwartz D and Schreiber D: The impact of adjuvant postoperative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma. Ann Surg. 265:1146–1151. 2017. View Article : Google Scholar : PubMed/NCBI
5	McDowell LJ, Huang SH, Xu W, Che J, Wong RKS, Brierley J, Kim J, Cummings B, Waldron J, Bayley A, et al: Effect of intensity modulated radiation therapy with concurrent chemotherapy on survival for patients with cervical esophageal carcinoma. Int J Radiat Oncol Biol Phys. 98:186–195. 2017. View Article : Google Scholar : PubMed/NCBI
6	Niezink AGH, de Jong RA, Muijs CT, Langendijk JA and Widder J: Pulmonary function changes after radiotherapy for lung or esophageal cancer: A systematic review focusing on dose-volume parameters. Oncologist. 22:1257–1264. 2017. View Article : Google Scholar : PubMed/NCBI
7	Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, et al: Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 3:1520–1528. 2017. View Article : Google Scholar : PubMed/NCBI
8	Takeuchi M, Suda K, Hamamoto Y, Kato M, Mayanagi S, Yoshida K, Fukuda K, Nakamura R, Wada N, Kawakubo H, et al: Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancer. Gastrointest Endosc. 88:456–465. 2018. View Article : Google Scholar : PubMed/NCBI
9	Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010 (ver.3). Gastric Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
10	Xu D, Li G, Li H and Jia F: Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: A systematic review and meta-analysis. Medicine (Baltimore). 96:e76852017. View Article : Google Scholar : PubMed/NCBI
11	Chen YJ, Liu A, Han C, Tsai PT, Schultheiss TE, Pezner RD, Vora N, Lim D, Shibata S, Kernstine KH, et al: Helical tomotherapy for radiotherapy in esophageal cancer: A preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim. 32:166–171. 2007. View Article : Google Scholar : PubMed/NCBI
12	Sun HT, Yang RJ, Jiang P, Jiang WJ, Li JN, Meng N and Wang JJ: Dosimetric analysis of volumetric modulated arc therapy and intensity modulated radiotherapy for patients undergone breast-conserving operation. Beijing Da Xue Xue Bao Yi Xue Ban. 50:188–192. 2018.(In Chinese). PubMed/NCBI
13	Subbiah V, Chuang HH, Gambhire D and Kairemo K: Defining clinical response criteria and early response criteria for precision oncology: Current state-of-the-art and future perspectives. Diagnostics (Basel). 7:102017. View Article : Google Scholar
14	Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, et al: NRG oncology RTOG 9006: A phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol. 137:39–47. 2018. View Article : Google Scholar : PubMed/NCBI
15	Abraham JM and Meltzer SJ: Long noncoding RNAs in the pathogenesis of Barrett's esophagus and esophageal carcinoma. Gastroenterology. 153:27–34. 2017. View Article : Google Scholar : PubMed/NCBI
16	Muto M, Ohtsu A, Miyata Y, Shioyama Y, Boku N and Yoshida S: Self-expandable metallic stents for patients with recurrent esophageal carcinoma after failure of primary chemoradiotherapy. Jpn J Clin Oncol. 31:270–274. 2001. View Article : Google Scholar : PubMed/NCBI
17	Liu S, Anfossi S, Qiu B, Zheng Y, Cai M, Fu J, Yang H, Liu Q, Chen Z, Fu J, et al: Prognostic factors for locoregional recurrence in patients with thoracic esophageal squamous cell carcinoma treated with radical two-field lymph node dissection: results from long-term follow-up. Ann Surg Oncol. 24:966–973. 2017. View Article : Google Scholar : PubMed/NCBI
18	Deng JY, Wang C, Shi XH, Jiang GL, Wang Y, Liu Y and Zhao KL: Reduced toxicity with three-dimensional conformal radiotherapy or intensity-modulated radiotherapy compared with conventional two-dimensional radiotherapy for esophageal squamous cell carcinoma: A secondary analysis of data from four prospective clinical trials. Dis Esophagus. 29:1121–1127. 2016. View Article : Google Scholar : PubMed/NCBI
19	Nishiyama K, Kozuka T, Higashihara T, Miyauchi K and Okagawa K: Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys. 36:1221–1224. 1996. View Article : Google Scholar : PubMed/NCBI
20	Yang H, Feng C, Cai BN, Yang J, Liu HX and Ma L: Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical esophageal carcinoma. Dis Esophagus. 30:1–8. 2017.
21	Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW and Kestin LL: Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: A comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 57:875–890. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, Ramnath N, Hassan KA, Matuszak M, Ritter T, et al: Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: A phase 2 clinical trial. JAMA Oncol. 3:1358–1365. 2017. View Article : Google Scholar : PubMed/NCBI
23	Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA and Perez CA: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:323–329. 1999. View Article : Google Scholar : PubMed/NCBI
24	Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD, et al: Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 68:94–102. 2007. View Article : Google Scholar : PubMed/NCBI
25	De Felice F, de Vincentiis M, Luzzi V, Magliulo G, Tombolini M, Ruoppolo G and Polimeni A: Late radiation-associated dysphagia in head and neck cancer patients: Evidence, research and management. Oral Oncol. 77:125–130. 2018. View Article : Google Scholar : PubMed/NCBI